Sartorius Addresses Structural Manufacturing Bottlenecks with Launch of Eveo Cell Therapy Platform

Summary

Sartorius is launching the Eveo Cell Therapy Platform, an integrated, modular system that consolidates cell selection, activation, gene editing, expansion, washing, concentration and formulation into a closed, compact footprint. The platform can process eight autologous patient batches simultaneously, boosting annual output from roughly 100 to over 350 doses and cutting manufacturing costs by about 90%, while fitting into existing facilities and lower‑classification cleanrooms. Developed with CDMO ElevateBio, the system passed pilot testing and will be available for order in September 2026 with deliveries slated for 2027.